Autor: |
Tometich DB; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL 33612, USA., Hoogland AI; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL 33612, USA., Small BJ; School of Aging Studies, University of South Florida, Tampa, FL 33620, USA., Janelsins MC; Department of Surgery and Neuroscience, University of Rochester Medical Center, Rochester, NY 14642, USA., Bryant C; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL 33612, USA., Rodriguez Y; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL 33612, USA., Gonzalez BD; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL 33612, USA., Li X; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL 33612, USA., Bulls HW; Section of Palliative Care and Medical Ethics, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA., James BW; Morsani College of Medicine, University of South Florida, Tampa, FL 33620, USA., Arboleda B; Morsani College of Medicine, University of South Florida, Tampa, FL 33620, USA., Colon-Echevarria C; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA., Townsend MK; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA., Tworoger SS; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA., Rodriguez P; Department of Immunology, Moffitt Cancer Center, Tampa, FL 33612, USA., Oswald LB; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL 33612, USA., Bower JE; Department of Psychology, University of California Los Angeles, Los Angeles, CA 90095, USA., Apte SM; Huntsman Cancer Institute, Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT 84112, USA., Wenham RM; Department of Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Chon HS; Department of Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Shahzad MM; Department of Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Jim HSL; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL 33612, USA. |
Abstrakt: |
Little is known regarding associations between inflammatory biomarkers and objectively measured physical activity and sleep during and after chemotherapy for gynecologic cancer; thus, we conducted a longitudinal study to address this gap. Women with gynecologic cancer (patients) and non-cancer controls (controls) completed assessments before chemotherapy cycles 1, 3, and 6 (controls assessed contemporaneously), as well as at 6- and 12-month follow-ups. Physical activity and sleep were measured using wrist-worn actigraphs and sleep diaries, and blood was drawn to quantify circulating levels of inflammatory markers. Linear and quadratic random-effects mixed models and random-effects fluctuation mixed models were used to examine physical activity and sleep over time, as well as the associations with inflammatory biomarkers. On average, patients ( n = 97) and controls ( n = 104) were 62 and 58 years old, respectively. Compared to controls, patients were less active, more sedentary, had more time awake after sleep onset, and had lower sleep efficiency ( p -values < 0.05). Across groups, higher levels of TNF-α were associated with more sedentary time and less efficient sleep ( p -values ≤ 0.05). Higher levels of IL-1β, TNF-α, and IL-6 were associated with lower levels of light physical activity ( p -values < 0.05). Associations between inflammatory biomarkers, physical activity, and sleep did not differ between patients and controls. Given these results, we speculate that inflammation may contribute to less physical activity and more sleep problems that persist even 12 months after completing chemotherapy. |